TMS (Transcranial Magnetic Stimulation) — Cognitive Technologies & Brain Longevity
FDA-cleared non-invasive brain stimulation using pulsed magnetic fields for treatment-resistant depression, OCD, anxious depression, and smoking cessation.
Overview
Transcranial Magnetic Stimulation (TMS) uses a rapidly alternating magnetic field to induce electrical currents in superficial cortical neurons, producing direct neuronal depolarization — unlike tDCS which only modulates membrane potential. Repetitive TMS (rTMS) at specific frequencies (high-frequency 10 Hz over left DLPFC is excitatory; low-frequency 1 Hz is inhibitory) produces lasting changes in cortical excitability and connectivity. FDA cleared rTMS for treatment-resistant depression (2008, NeuroStar), OCD (2018, BrainsWay dTMS), anxious depression (2021), and smoking cessation (2020, BrainsWay). A 2020 meta-analysis of 81 RCTs (n=4,233) found active rTMS produced 2.2x higher response rate than sham. Accelerated TMS protocols (iTBS — intermittent theta burst stimulation) deliver compressed courses: the Stanford SAINT protocol (10 sessions/day x 5 days in 1 week) achieved 79% remission rate in TRD patients in the Phase 2 trial. Standard TMS requires 36 sessions over 6 weeks at a clinical facility; iTBS is completed in days, and home TMS devices (Magstim, BrainsWay home) are in development.
Indications
- Treatment-resistant depression (≥ 2 failed antidepressants) — FDA-cleared
- Obsessive-compulsive disorder (OCD) — FDA-cleared
- Anxious depression — FDA-cleared
- Smoking cessation — FDA-cleared
- PTSD (off-label, promising research)
- Cognitive rehabilitation post-stroke or TBI (off-label)
Mechanism of Action
A brief, intense magnetic pulse (1-2 Tesla) from the TMS coil induces sufficient electrical current in cortical neurons to trigger action potentials — the most direct non-surgical method of neuronal activation available
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Standard rTMS (Left DLPFC, 10 Hz) | 10 Hz, 120% motor threshold, 3,000 pulses per session | 5 days/week x 6-7 weeks (30-36 sessions total) | FDA-cleared protocol; NeuroStar, MagVenture, Nexstim systems; cost $6,000-12,000 total; often partially covered by insurance for TRD |
| Accelerated TMS / Stanford SAINT Protocol (iTBS) | 600 pulses iTBS (50 Hz triplets at 5 Hz), 10 sessions per day | 10 sessions/day x 5 days = 50 sessions total in 1 week | Dramatically compressed timeline; 79% remission in Phase 2 (n=29); Phase 3 trial ongoing; MRI neuronavigation adds precision and cost |
Evidence Grade
GRADE A
Safety & Contraindications
- Seizure risk: rare (1:30,000 standard rTMS; higher with off-label aggressive protocols) — contraindicated with seizure disorder, certain medications, or metal implants near head
- Headache and scalp discomfort at stimulation site (30-50% of patients) — usually mild and resolves
- Hearing protection required during treatment (magnetic pulse produces loud click)
- Contraindicated: metallic implants in head, neck, or upper chest (aneurysm clips, cochlear implants, deep brain stimulators, vagus nerve stimulators)
- Contraindicated: cardiac pacemakers or defibrillators
- Must be administered in clinical setting by trained TMS operator (non-negotiable for safety)